Valuation check: IMMP's ROE is -229.5%, below the Healthcare sector average of 21.28%.
Get informed when a big investor buys or sells
+ Follow-229.50%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Immutep Limited (IMMP) currently reports a ROE of -229.5%. That is below the Healthcare sector average of 21.28%. Use the charts on this page to explore Immutep Limited's ROE history and peer comparisons.
Immutep Limited's ROE of -229.5% is lower than the Healthcare sector average of 21.28%. That is roughly 1178.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Immutep Limited's current -229.5% should be judged against Healthcare norms (sector average: 21.28%) and against IMMP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -229.5%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.28%. From there, open related valuation or income-statement pages for Immutep Limited, and consider following IMMP for alerts when major investors trade the stock.
Immutep Limited is classified in the Healthcare sector. On ROE, it currently shows -229.5% versus a sector average near 21.28%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IMMP with unrelated industries.